COMPANY PROFILE

Augmenix

Explore full profile

SpaceOAR Advanced Hydrogel Products for Radiotherapy | Augmenix

Waltham, United StatesFounded 2008Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2018

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Augmenix

SpaceOAR Hydrogel is a medical device designed to minimize the side effects of radiation therapy for prostate cancer patients by creating a protective space between the rectum and the prostate. This innovative hydrogel spacer reduces the likelihood of high-dose radiation reaching the rectum, thereby improving the quality of life for patients undergoing prostate cancer treatment. The company primarily serves healthcare providers and prostate cancer patients, operating within the medical device market. SpaceOAR Hydrogel is FDA cleared and has been validated through extensive clinical research, with over 220,000 patients treated worldwide. The business model revolves around the sale of the hydrogel product to medical institutions and practitioners, generating revenue through product sales and potentially through partnerships with healthcare providers.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2008
Headquarters: Waltham, United States
Open positions: None listed
Dealroom signal: 21.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Testing, Risk Management, Biotechnology, Oncology, Surgery, Hard Tech, medical testing, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Sep 2018	$600M	$600M	Boston Scientific	—
SERIES EEquity / VC	Jul 2016	$6M	$24M	Catalyst Health Ventures · Catalyst Health Ventures	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Augmenix website traffic

Latest recorded traffic for Augmenix is 5.1K monthly website visits, down 1.9% over the last three months.

Latest monthly visits5.1K 3-month web change-1.9%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ODOncoStem DiagnosticsDiagnostic oncology company focused on discovering and developing novel tests for improved treatment planning	Bengaluru, India	Operational	23	$7M	$24M
PGPathway GenomicsGlobal clinical lab offering genetic tests for cancer risk, drug responses, and many other conditions	San Diego, United States	Operational
BIBioprognosEarly cancer diagnosis via a blood test	Barcelona, Spain	Operational
2S20/20 Gene SystemsDevelop and promote innovative tools for biotech	Gaithersburg, United States	Operational
IAImaging AdvantageCloud-based radiology solutions for healthcare facilities	Santa Monica, United States	Acquired
DTDIR TechnologiesThermography-based inspection solutions for packaging quality assurance	Haifa, Israel	Operational
ADArquer DiagnosticsArquer Diagnostics is a diagnostics company focused on the development and commercialisation of a non-invasive immunoassay diagnostic test	Sunderland, United Kingdom	Closed
DIDiaCartaImproving patient care through novel precision molecular diagnostics: CE/IVD marked tests are available for detection of KRAS	Hayward, United States	Operational